CC BY-NC-ND 4.0 · South Asian J Cancer 2023; 12(04): 334-340
DOI: 10.1055/s-0043-1771444
Original Article
Gynaecological Cancer

Critical Analysis of Advanced High-Grade Serous Epithelial Ovarian Cancer in Women: An Experience of 100 Cases from a Regional Cancer Center in Northeast India

Debabrata Barmon
1   Department of Gynaecologic Oncology, Dr. Bhubaneswar Borooah Cancer Institute, Guwahati, Assam, India
Sharda Patra
1   Department of Gynaecologic Oncology, Dr. Bhubaneswar Borooah Cancer Institute, Guwahati, Assam, India
Megha Nandwani
1   Department of Gynaecologic Oncology, Dr. Bhubaneswar Borooah Cancer Institute, Guwahati, Assam, India
Roma Jethani
1   Department of Gynaecologic Oncology, Dr. Bhubaneswar Borooah Cancer Institute, Guwahati, Assam, India
A. C. Kataki
2   Department of Gynaecological Oncology, Dr. Bhubaneswar Borooah Cancer Institute, Guwahati, Assam, India
› Author Affiliations


Zoom Image
Debabrata Barmon

Ovarian cancer is the sixth most common cancer in women worldwide. Patients with ovarian carcinoma mostly present at an advanced stage with serous type of epithelial ovarian cancers, which is the most lethal of all pelvic malignancies. This study aims to critically analyze high-grade serous epithelial ovarian carcinomas in women from the Northeastern region of India and compare our data with Western literature to modify treatment strategies and improve survival outcomes. This hospital-based retrospective analysis involved data from the records of 100 women with high-grade epithelial ovarian cancer treated primarily with neoadjuvant chemotherapy followed by interval debulking surgery in the department of gynecologic oncology at a tertiary level regional cancer institute from January 2018 to December 2019. The demographic, clinical and pathological profile, and survival outcome were evaluated using descriptive statistics. The overall survival of the study population was calculated using Kaplan–Meier curves using SPSS software (version 24). The majority of women belonged to 41 to 55 years age group. At first presentation to the hospital, 89 and11% patients were in stage III and stage IV of disease, respectively. Clinically, 95% of women had ascites, and 18% had metastasis to lymph nodes. Distant metastasis to lungs and liver was present in 10 and 3% of cases, respectively. A substantial percentage (98%) of women had raised serum Ca125 > 1000 at baseline, ranging from 1,745 to 10,987 IU/mL. Almost two-thirds of the cases had partial-to-complete response to neoadjuvant chemotherapy (78%). In most of the women (72%), there was no residual disease at interval debulking surgery (R0), though 28% women had R1& R2 resection. The median overall survival time was 36 months. High-grade serous ovarian cancer is commonly seen in older age group, but its occurrence in younger population has also been observed. Early diagnosis is crucial in decreasing morbidity and mortality among these patients. Therefore, efforts should be made to identify risk factors for malignancy. Assessing each parameter of statistical information reflecting its own profile may be important for calculating the risk for the development of ovarian cancer, which can help in implementing preventive measures in the future.

Publication History

Article published online:
07 August 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 Torre LA, Trabert B, DeSantis CE. et al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018; 68 (04) 284-296
  • 2 Foley OW, Rauh-Hain JA, del Carmen MG. Recurrent epithelial ovarian cancer: an update on treatment. Oncology (Williston Park) 2013; 27 (04) 288-294 , 298
  • 3 Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007; 14 (05) 195-208
  • 4 Hanker LC, Loibl S, Burchardi N. et al; AGO and GINECO study group. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 2012; 23 (10) 2605-2612
  • 5 Heintz AP, Odicino F, Maisonneuve P. et al. Carcinoma of the ovary. Int J Gynaecol Obstet 2003; 83 (Suppl. 01) 135-166
  • 6 Therasse P, Arbuck SG, Eisenhauer EA. et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92 (03) 205-216
  • 7 Muraji M, Sudo T, Iwasaki S. et al. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery. Gynecol Oncol 2013; 131 (03) 531-534
  • 8 Vergote I, Tropé CG, Amant F. et al; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363 (10) 943-953
  • 9 Kehoe S, Hook J, Nankivell M. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386 (9990) 249-257
  • 10 Maheshwari A, Kumar N, Gupta S. et al. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Indian J Cancer 2018; 55 (01) 50-54
  • 11 Baruah U, Barmon D, Kataki AC, Deka P, Hazarika M, Saikia BJ. Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a survival study. Indian J Med Paediatr Oncol 2015; 36 (01) 38-42
  • 12 Fagotti A, Ferrandina G, Vizzielli G. et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer 2016; 59: 22-33
  • 13 Vishwanath, Shetty PK, Beegum M. Neoadjuvant chemotherapy in advanced stage ovarian cancer. Int J Clin Obstetr Gynaecol 2018; 2 (06) 103-109
  • 14 Deo SVS, Goyal H, Shukla NK, Raina V, Kumar L, Srinivas G. Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer. Indian J Cancer 2006; 43 (03) 117-121
  • 15 Batra S, Nayak H, Dave KS. Role of neoadjuvant chemotherapy (NACT) followed by surgical cytoreduction in advanced epithelial ovarian cancer. J Obstet Gynaecol India 2012; 62 (05) 541-545
  • 16 Ghisoni E, Katsaros D, Maggiorotto F. et al. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience. J Ovarian Res 2018; 11 (01) 42
  • 17 Onda T, Satoh T, Saito T. et al; Japan Clinical Oncology Group. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer 2016; 64: 22-31
  • 18 Le T, Williams K, Senterman M, Hopkins L, Faught W, Fung-Kee-Fung M. Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Gynecol Oncol 2007; 106 (01) 160-163
  • 19 Wang Y, Wang Y, Zheng W. Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy. Int J Clin Exp Pathol 2013; 6 (10) 2121-2128
  • 20 Ferron JG, Uzan C, Rey A. et al. Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease. Eur J Obstet Gynecol Reprod Biol 2009; 147 (01) 101-105
  • 21 Petrillo M, Zannoni GF, Tortorella L. et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. Am J Obstet Gynecol 2014; 211 (06) 632.e1-632.e8
  • 22 Böhm S, Faruqi A, Said I. et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol 2015; 33 (22) 2457-2463
  • 23 Wang D, Zhang G, Peng C, Shi Y, Shi X. Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study. J Ovarian Res 2021; 14 (01) 49
  • 24 Lee YJ, Chung YS, Lee JY. et al. Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer. Gynecol Oncol 2018; 148 (01) 62-67
  • 25 Searle G, Pounds R, Phillips A. et al. Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis. Gynecol Oncol 2020; 158 (01) 54-58
  • 26 Chen M, Chen Z, Xu M. et al. Impact of the time interval from neoadjuvant chemotherapy to surgery in primary ovarian, tubal, and peritoneal cancer patients. J Cancer 2018; 9 (21) 4087-4091
  • 27 Petrillo M, Ferrandina G, Fagotti A. et al. Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. Ann Surg Oncol 2013; 20 (12) 3955-3960
  • 28 da Costa AA, Valadares CV, Baiocchi G. et al. Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer. Ann Surg Oncol 2015; 22 (Suppl. 03) S971-S978